Breaking News

Theseus Pharmaceuticals announced initial dose escalation data from the ongoing phase 1/2 trial of THE-630 in patients with advanced gastrointestinal stromal tumors. Theseus will host a virtual investor webcast today at 5:30pm ET to discuss this update. "THE-630 has shown strong clinical proof of mechanism through Cohort 6 with a safety and pharmacokinetic profile supportive of continued dose escalation," said Tim Clackson, Ph.D., President and CEO. "Importantly, with dose-dependent activity observed against both major classes of KIT resistance mutations, coupled with the increased frequency of stable disease at the higher doses tested thus far, we believe THE-630 could have a best-in-class profile and provide a much-needed alternative to combat the complex resistance that drives rapid progression of GIST. We are also encouraged by the further validation of our PRA, with reductions in ctDNA observed for specific mutations consistent with our preclinical predictions. These data support our ability to reach target exposures in Cohort 8, and we look forward to reporting data through Cohort 8 later this year."

Affimed N.V. "announced the publication of two abstracts with its innate cell engager AFM24 in advance of the American Society of Clinical Oncology Annual Meeting, taking place on June 2 - 6, 2023 in Chicago, IL. As of the December cut-off data for the abstract, 14 patients were enrolled in the EGFR mutant NSCLC cohort and the best objective response in 10 evaluable patients was a confirmed partial response in 1 patient (change from baseline -45%); 4 patients exhibited stable disease of which two had tumor shrinkage. AFM24 exhibited a well-managed safety profile and the most common treatment-related adverse events observed were mild to moderate infusion-related reactions. Updated data with a cut-off date of mid-April 2023 will be presented by Dr. Anthony El-Khoueiry, Associate Director of Clinical Research at USC Norris Comprehensive Cancer Center, at ASCO on June 3, 2023 during the poster session on Developmental Therapeutics - Immunotherapy. Dr. El-Khoueiry's presentation will include data from 15 evaluable patients."